Abstract 14P
Background
Small cell lung cancer (SCLC) is a lethal neoplasia. Chemotherapy (Ct) plus immune checkpoint blockade therapy (ICBt) is now the standard of care although limited survival benefit. Lack of biomarkers of response leads to suboptimal patient selection, distorting results of clinical trials. Deciphering the ICBt-driven peripheral immune events may recognize those patients who benefit the most. Here, we characterize early peripheral immune kinetics in SCLC patients treated with Ct + ICBt with improved survival.
Methods
SCLC patients from 8 centers were prospectively recruited into 3 cohorts. Cohort 1 include patients treated with Ct (n=24). Cohort 2 (n=37) comprise patients treated with Ct + anti-CTLA-4, and cohort 3 (n=20) patients treated with Ct + anti-PD-1/PD-L1. Peripheral blood mononuclear cells were obtained prior to treatment and after the first dose of ICBt. Variation in proliferation, senescence, adhesion, immunosuppression, and checkpoints markers was assessed by FACS. Kaplan–Meier and log-rank test were used for survival analysis. MaxStat was used to calculate cut points. A p-value <0.05 was considered statistically significant.
Results
We found 6 independent cellular subsets which modulation right after the start of ICBt identify patients with improved survival. An increase in CD8+CD103+Ki67+ cells identify survival benefit in cohorts 1 and 3 (p=0.043; 0.0033). An upregulation of Ki67 in total CD4+ (p=0.012; 0.0027) and CD4+PD-1+ T cells (p=0.026; 0.027), predicts long survival in ICBt cohorts 2 and 3, while a downregulation of CD4+ICOS+ T cells (p=0.025; 0.011) identified survival benefit in these ICBt cohorts. Expansion of Ki67+ and ICOS+ (p=0.0024; 0.0074) CD8+ T cells was also observed in CD8+ T cells from long survivors exclusively from cohort 2.
Conclusions
Expansion of CD8+CD103+Ki67+, CD4+Ki67+, and CD4+PD-1+Ki67+, or a reduction in CD4+ICOS+ circulating T cells subsets identify long survival patients treated with anti-CTLA-4 or anti-PD-1/PD-L1, while an increase in CD8+Ki67+ or CD8+ICOS+ cells predicts benefit only in patients treated with anti-CTLA-4. Assessment of the immune kinetics of these peripheral cellular subsets identify patients who benefit the most from ICBt in SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fundació Amics de l'Hospital del Mar.
Disclosure
E. Arriola: Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional funding, Travel and educational expenses: BMS, MSD; Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional and Research funding, Travel and educational expenses: Roche; Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional and Research funding: Pfizer; Financial Interests, Personal, Advisory Role, Speaker, Travel and educational expenses: Lilly; Financial Interests, Personal and Institutional, Advisory Role, Speaker, Institutional funding: AstraZeneca; Financial Interests, Personal, Advisory Role, Speaker: Boehringer Ingelheim, Takeda; Other, Personal, Member of Board of Directors, Co-founder: TrialingHealth. All other authors have declared no conflicts of interest.
Resources from the same session
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09